Top

Published in:

01-04-2013 | Epidemiology

Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women

Authors: Bassam Lajin, Amir Alhaj Sakur, Amal Alachkar

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Abstract

Apoptosis is a major protective mechanism against cancer. The tumor suppressor protein p53 is the central protein in the apoptotic pathway and was shown to harbor mutations in a considerable fraction of breast cancer tumors. The NQO1 was shown to act as a p53 stabilizer and was suggested to play an important role in the protection against carcinogenic catechol estrogens. Functional polymorphisms in TP53 and NQO1 were investigated in relation to breast cancer susceptibility in several studies, primarily involving Asian and Caucasian populations. The aim of the present study was to investigate TP53 and NQO1 polymorphisms and their combined effects with respect to breast cancer susceptibility in a Syrian study cohort. The study cohort consisted of 122 cases and 139 controls. The tetra-primer ARMS-PCR method was used to genotype three TP53 polymorphisms; namely, exon 4 G>C Arg72Pro, IVS3 16 bp Del/Ins, and MspI IVS6+62A>G, and NQO1 C609T (Pro187Ser) polymorphism. Association was tested under six genetic models. We found a significant association for the heterozygous Arg/Pro genotype when combined with heterozygosity for IVS3 16 bp Del/Ins and MspI IVS6+62A>G (OR = 2.05 (1.22–3.47), P = 0.006). No significant association was found for NQO1 C609T or its combinations with TP53 polymorphisms. Our results support an association for TP53 polymorphisms with breast cancer susceptibility in the Syrian population.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010

Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886PubMedCrossRef

el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Gene 1(1):45–49CrossRef

Roy B, Beamon J, Balint E, Reisman D (1994) Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 14(12):7805–7815PubMed

Pavletich NP, Chambers KA, Pabo CO (1993) The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7(12B):2556–2564PubMedCrossRef

Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A et al (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39(Database issue):D945–D950PubMedCrossRef

Asher G, Lotem J, Cohen B, Sachs L, Shaul Y (2001) Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA 98(3):1188–1193PubMedCrossRef

Bianco NR, Perry G, Smith MA, Templeton DJ, Montano MM (2003) Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage. Mol Endocrinol 17(7):1344–1355PubMedCrossRef

Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S et al (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10(4):307–311PubMedCrossRef

10.

Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6(2):105–112PubMed

11.

Buyru N, Tigli H, Dalay N (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10(3):711–714PubMed

12.

Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, Friedman E (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92(6):1144–1148PubMedCrossRef

13.

Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, Alexandre CO (2006) Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30(6):523–529PubMedCrossRef

14.

Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grunewald K, Haun M, Kraft HG (2004) Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 90(10):1989–1994PubMedCrossRef

15.

Aston CE, Ralph DA, Lalo DP, Manjeshwar S, Gramling BA, DeFreese DC, West AD, Branam DE, Thompson LF, Craft MA et al (2005) Oligogenic combinations associated with breast cancer risk in women under 53 years of age. Hum Genet 116(3):208–221PubMedCrossRef

16.

Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, Rodriguez C, Thun MJ, Calle EE (2007) Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 16(9):1784–1794PubMedCrossRef

17.

Sarmanova J, Susova S, Gut I, Mrhalova M, Kodet R, Adamek J, Roth Z, Soucek P (2004) Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Genet 12(10):848–854PubMedCrossRef

18.

Siegelmann-Danieli N, Buetow KH (2002) Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H: quinone oxidoreductase 1 detoxification genes in breast cancer development. Oncology 62(1):39–45PubMedCrossRef

19.

Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, Rafeek M, Akil N, Alkhalaf M (2011) P53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol 28(3):709–715PubMedCrossRef

20.

Trifa F, Karray-Chouayekh S, Mabrouk I, Baccouche S, Khabir A, Sellami-Boudawara T, Gargouri A, Mokdad-Gargouri R (2010) Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16 bp and G13964C in Tunisian patients with familial or sporadic breast cancer. Cancer Epidemiol 34(2):184–188PubMedCrossRef

21.

Lajin B, Alachkar A, Alhaj Sakur A (2012) A quadruplex tetra-primer ARMS-PCR method for the simultaneous detection of TP53 Arg72Pro, IVS3 16 bp Del/Ins and IVS6+62A>G, and NQO1 C609T polymorphisms. Gene 504(2):268–273PubMedCrossRef

22.

Slatkin M, Excoffier L (1996) Testing for linkage disequilibrium in genotypic data using the expectation-maximization algorithm. Heredity 76(Pt 4):377–383PubMedCrossRef

23.

Yoo J, Lee Y, Kim Y, Rha SY, Kim Y (2008) SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis. BMC Bioinform 9:290CrossRef

24.

Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33(3):357–365PubMedCrossRef

25.

Brooks LA, Tidy JA, Gusterson B, Hiller L, O’Nions J, Gasco M, Marin MC, Farrell PJ, Kaelin WG Jr, Crook T (2000) Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 60(24):6875–6877PubMed

26.

Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B et al (2004) Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 164(4):1233–1241PubMedCrossRef

27.

Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, Tanaka S, Sugimachi K (2000) p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res 60(11):2753–2755PubMed

28.

Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A (2004) Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 6(5):529–535PubMedCrossRef

29.

Marin MC, Jost CA, Brooks LA, Irwin MS, O’Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG et al (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25(1):47–54PubMedCrossRef

30.

van Duin M, Snijders PJ, Vossen MT, Klaassen E, Voorhorst F, Verheijen RH, Helmerhorst TJ, Meijer CJ, Walboomers JM (2000) Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 81(Pt 2):317–325PubMed

31.

Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V (1999) Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 6(1):193–197PubMed

32.

Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393(6682):229–234PubMedCrossRef

33.

Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, Su L (2010) Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis 31(4):643–647PubMedCrossRef

34.

Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G et al (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23(10):1954–1956PubMedCrossRef

35.

He XF, Su J, Zhang Y, Huang X, Liu Y, Ding DP, Wang W, Arparkorn K (2011) Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat 130(2):517–529PubMedCrossRef

36.

Nikbakht Dastjerdi M, Mirmohammad SH (2010) TP53 codon 72 heterozygosity may promote microsatellite instability in sporadic colorectal cancer. YAKHTEH 12:1–6

37.

Toyama T, Iwase H, Yamashita H, Iwata H, Yamashita T, Ito K, Hara Y, Suchi M, Kato T, Nakamura T et al (1996) Microsatellite instability in sporadic human breast cancers. Int J Cancer 68(4):447–451PubMedCrossRef

38.

Anbazhagan R, Fujii H, Gabrielson E (1999) Microsatellite instability is uncommon in breast cancer. Clin Cancer Res 5(4):839–844PubMed

39.

Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa AE (2008) High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer 99(3):404–407PubMedCrossRef

40.

Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, Min HK, Lee JM, Namkoong SE (2000) Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer 88(9):2082–2091PubMedCrossRef

41.

Klug SJ, Wilmotte R, Santos C, Almonte M, Herrero R, Guerrero I, Caceres E, Peixoto-Guimaraes D, Lenoir G, Hainaut P et al (2001) TP53 polymorphism, HPV infection, and risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 10(9):1009–1012PubMed

42.

Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D (2001) Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol 59(2):263–268PubMed

43.

Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69(7):1237–1245PubMedCrossRef

44.

Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5):591–602PubMedCrossRef

45.

Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP (2011) Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers 15(5):343–349PubMedCrossRef

46.

Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, Hatooka S, Mitsudomi T, Suyama M, Kagami Y et al (2002) NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 7(2):103–108PubMed

47.

Fowke JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT, Zheng W (2004) Oral contraceptive use and breast cancer risk: modification by NAD(P)H: quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 13(8):1308–1315PubMed

48.

Yuan W, Xu L, Chen W, Wang L, Fu Z, Pang D, Li D (2011) Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat 125(2):467–472PubMedCrossRef

49.

Al-Qasem A, Toulimat M, Tulbah A, Elkum N, Al-Tweigeri T, Aboussekhra A (2012) The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett 3(4):875–878PubMed

50.

Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L (1994) Is p53 polymorphism maintained by natural selection? Hum Hered 44(5):266–270PubMedCrossRef

51.

Al-Qasem AJ, Toulimat M, Eldali AM, Tulbah A, Al-Yousef N, Al-Daihan SK, Al-Tassan N, Al-Tweigeri T, Aboussekhra A (2011) TP53 genetic alterations in Arab breast cancer patients: novel mutations, pattern and distribution. Oncol Lett 2(2):363–369PubMed

52.

Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94(9):681–690PubMedCrossRef

Title: Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women
Authors: Bassam Lajin
Amir Alhaj Sakur
Amal Alachkar
Publication date: 01-04-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2467-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response

Body size throughout the life course and mammographic density in Mexican women

Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?

The protective effect of intermittent calorie restriction on mammary tumorigenesis is not compromised by consumption of a high fat diet during refeeding

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial

The prognostic impact of age in patients with triple-negative breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer